Combinatorial Targeting of the Cell Cycle and Key Interacting Pathways in Mesothelioma
Congressional District Code:
Biomedical Laboratory R&D
April 2020 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
The Problem: Mesothelioma is a devastating cancer where the majority of patients will die from their disease. The last significant advance in chemotherapy for mesothelioma was pemetrexed, which was approved by the FDA in 2004. The vast majority of mesothelioma tumors have defects in the cell cycle. Low expression of the CDK4/CDK6 inhibitor p16INK4a has been demonstrated in multiple basic and clinical studies of mesothelioma. A phase III study reported a significant increase in survival in breast...